The estimated Net Worth of Paul Brannelly is at least 6.46 百万$ dollars as of 21 June 2018. Mr. Brannelly owns over 10,000 units of Collegium Pharmaceutical Inc stock worth over 4,468,383$ and over the last 11 years he sold COLL stock worth over 279,200$. In addition, he makes 1,713,770$ as Chief Financial Officer、 Executive Vice President at Collegium Pharmaceutical Inc.
Paul has made over 5 trades of the Collegium Pharmaceutical Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of COLL stock worth 279,200$ on 21 June 2018.
The largest trade he's ever made was selling 10,000 units of Collegium Pharmaceutical Inc stock on 21 June 2018 worth over 279,200$. On average, Paul trades about 682 units every 45 days since 2013. As of 21 June 2018 he still owns at least 123,436 units of Collegium Pharmaceutical Inc stock.
You can see the complete history of Mr. Brannelly stock trades at the bottom of the page.
Paul Brannelly CPA serves as Chief Financial Officer, Executive Vice President of the Company. since February 2015. Mr. Brannelly has served as our Executive Vice President and Chief Financial Officer since February 2015. Prior to joining us, Mr. Brannelly served as Senior Vice President, Finance and Administration, and Treasurer of Karyopharm Therapeutics Inc., a biopharmaceutical company, from June 2013 to August 2014. From August 2014 to November 2014, Mr. Brannelly served as a consultant to Karyopharm. Prior to joining Karyopharm, Mr. Brannelly served as Vice President, Finance, Treasurer and Secretary at Verastem, Inc. from August 2010 to May 2013. From January 2010 to September 2011, Mr. Brannelly held the position of Chief Financial Officer at the Longwood Fund, a venture capital firm aimed at investing in, managing and building healthcare companies, where he set up the financial and operational infrastructure following the closing of its first fund and eventually served as Chief Financial Officer of its first two startup companies, Verastem and OvaScience, Inc. From November 2005 to September 2009, he served as Vice President, Finance at Sirtris Pharmaceuticals, Inc., a biopharmaceutical company which GlaxoSmithKline plc purchased for $720 million in 2008, where he managed the Form S-1 preparation and due diligence process for Sirtris’ initial public offering and managed the company’s transition to being a public company. Mr. Brannelly started his biopharmaceutical career at Dyax Corporation from September 1999 to May 2002, and subsequently moved on to positions of increasing responsibility at CombinatoRx Inc. from May 2002 to November 2005, including as Vice President, Finance and Treasurer, where he led the initial public offering process. Mr. Brannelly graduated from the University of Massachusetts at Amherst with a B.B.A. in Accounting in 1995.
As the Chief Financial Officer、 Executive Vice President of Collegium Pharmaceutical Inc, the total compensation of Paul Brannelly at Collegium Pharmaceutical Inc is 1,713,770$. There are 3 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of 4,032,630$.
Paul Brannelly is 47, he's been the Chief Financial Officer、 Executive Vice President of Collegium Pharmaceutical Inc since 2015. There are 15 older and 3 younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.
Paul's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.
Over the last 10 years, insiders at Collegium Pharmaceutical Inc have traded over 80,399,308$ worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth 13,316,951$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、John Gordon Freund、David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of 2,130,406$. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth 773,809$.
collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex
Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include: